Abstract
Originalsprog | Engelsk |
---|---|
Tidsskrift | Critical Care (Online Edition) |
Vol/bind | 14 |
Udgave nummer | 2 |
Sider (fra-til) | R28 |
ISSN | 1466-609X |
DOI | |
Status | Udgivet - 1 jan. 2010 |
Adgang til dokumentet
Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Influence of Factor V Leiden on susceptibility to and outcome from critical illness: a genetic association study. / Benfield, Thomas; Ejrnæs, Karen; Juul, Klaus; Ostergaard, Christian; Helweg-Larsen, Jannik; Weis, Nina; Munthe-Fog, Lea; Kronborg, Gitte; Andersen, Marianne Ring; Tybjærg-Hansen, Anne; Nordestgaard, Børge G; Garred, Peter; Benfield, Thomas; Ejrnaes, Karen; Juul, Klaus; Andersen, Christian Østergaard; Helweg-Larsen, Jannik; Weis, Nina Margrethe; Munthe-Fog, Lea; Kronborg, Gitte; Andersen, Marianne Ring; Tybjaerg-Hansen, Anne; Nordestgaard, Børge G; Garred, Peter.
I: Critical Care (Online Edition), Bind 14, Nr. 2, 01.01.2010, s. R28.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Influence of Factor V Leiden on susceptibility to and outcome from critical illness: a genetic association study
AU - Benfield, Thomas
AU - Ejrnæs, Karen
AU - Juul, Klaus
AU - Ostergaard, Christian
AU - Helweg-Larsen, Jannik
AU - Weis, Nina
AU - Munthe-Fog, Lea
AU - Kronborg, Gitte
AU - Andersen, Marianne Ring
AU - Tybjærg-Hansen, Anne
AU - Nordestgaard, Børge G
AU - Garred, Peter
AU - Benfield, Thomas
AU - Ejrnaes, Karen
AU - Juul, Klaus
AU - Andersen, Christian Østergaard
AU - Helweg-Larsen, Jannik
AU - Weis, Nina Margrethe
AU - Munthe-Fog, Lea
AU - Kronborg, Gitte
AU - Andersen, Marianne Ring
AU - Tybjaerg-Hansen, Anne
AU - Nordestgaard, Børge G
AU - Garred, Peter
PY - 2010/1/1
Y1 - 2010/1/1
N2 - ABSTRACT: INTRODUCTION: Disturbance of the pro-coagulatant and anti-coagulant balance is associated with a poor outcome from critical illness. The objective of this study is to determine whether the Factor V Leiden (FVL) mutation is associated with susceptibility to or death from critical illness. METHODS: A genetic association study involving four case cohorts comprising two Gram negative sepsis, one invasive pneumococcal disease and one intensive care unit cohort with a total of 1,249 patients. Controls were derived from a population-based cohort study (N = 8,147). DNA from patients and controls was genotyped for the FVL mutation. RESULTS: When all patients were investigated together no significant difference in the frequency of FVL mutation was observed compared with controls (odds ratio (OR), 1.03; 95% confidence interval (CI), 0.83 to 1.29). However, when stratified among patients admitted to intensive care (N = 237), susceptibility and the likelihood of long-term death was influenced by the FVL mutation. In adjusted logistic regression analysis, FVL carriers had an increased risk of ICU admission compared to non-carriers (OR 1.62; 95% CI, 1.08 to 2.42). In adjusted Cox regression analysis, FVL carriers were at increased risk of long-term death compared to non-carriers (relative risk 1.78; 95% CI, 1.13 to 2.81). FVL carrier status did not predict either susceptibility to or outcome from Gram negative, Escherichia coli or Streptococcus pneumoniae sepsis. CONCLUSIONS: Overall, the FVL mutation did not appear to increase the risk of admission due to severe invasive infections. Nevertheless, in the subgroup of patients admitted to intensive care an increased risk and a poorer long-term outcome for individuals with critical illness were observed for FVL mutation carriers.
AB - ABSTRACT: INTRODUCTION: Disturbance of the pro-coagulatant and anti-coagulant balance is associated with a poor outcome from critical illness. The objective of this study is to determine whether the Factor V Leiden (FVL) mutation is associated with susceptibility to or death from critical illness. METHODS: A genetic association study involving four case cohorts comprising two Gram negative sepsis, one invasive pneumococcal disease and one intensive care unit cohort with a total of 1,249 patients. Controls were derived from a population-based cohort study (N = 8,147). DNA from patients and controls was genotyped for the FVL mutation. RESULTS: When all patients were investigated together no significant difference in the frequency of FVL mutation was observed compared with controls (odds ratio (OR), 1.03; 95% confidence interval (CI), 0.83 to 1.29). However, when stratified among patients admitted to intensive care (N = 237), susceptibility and the likelihood of long-term death was influenced by the FVL mutation. In adjusted logistic regression analysis, FVL carriers had an increased risk of ICU admission compared to non-carriers (OR 1.62; 95% CI, 1.08 to 2.42). In adjusted Cox regression analysis, FVL carriers were at increased risk of long-term death compared to non-carriers (relative risk 1.78; 95% CI, 1.13 to 2.81). FVL carrier status did not predict either susceptibility to or outcome from Gram negative, Escherichia coli or Streptococcus pneumoniae sepsis. CONCLUSIONS: Overall, the FVL mutation did not appear to increase the risk of admission due to severe invasive infections. Nevertheless, in the subgroup of patients admitted to intensive care an increased risk and a poorer long-term outcome for individuals with critical illness were observed for FVL mutation carriers.
U2 - 10.1186/cc8899
DO - 10.1186/cc8899
M3 - Journal article
C2 - 20202226
VL - 14
SP - R28
JO - Critical Care
JF - Critical Care
SN - 1364-8535
IS - 2
ER -